Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

    NEXT STORY
    Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
    PREV STORY
    Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Griffin-American Healthcare REIT IV Acquires Mint Hill Medical Office Building Near Charlotte

    CHARLOTTE, N.C., Nov. 18, 2016 (GLOBE NEWSWIRE) -- American Healthcare Investors and Griffin Capital ...

    author_avatar
    NASDAQ Market News

    G1 Therapeutics to Present Clinical and Preclinical Data on CDK4/6 Inhibitors G1T28 and G1T38 at the 2016 American Association for Cancer Research Annual Meeting

    Preliminary clinical data on G1T28 in combination with chemotherapy in newly diagnosed small-cell lung ...

    author_avatar
    NASDAQ Market News

    Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing

    DURHAM, N.C., June 16, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology ...

    author_avatar
    NASDAQ Market News